Summary
Chronic liver disease is known to alter the absorption and disposition of many drugs. To assess the influence of chronic alcoholic liver disease on the disposition of naproxen, we administered the drug both as a single dose and to steady state to 10 individuals with alcoholic cirrhosis and to 10 healthy controls. Plasma and serum samples collected after naproxen dosing were assayed for both total and (following equilibrium dialysis) unbound drug concentration. Clearance calculated based on both total and unbound naproxen concentration revealed no change in total plasma clearance of the drug at steady state but a marked reduction of approximately 60% in clearance based on unbound drug. Naproxen volume of distribution changed only minimally. Because clearance based on unbound drug concentration at a given dosing rate determines the plasma or blood free drug concentration, this concentration may increase significantly in patients with alcoholic liver disease given usual doses of naproxen. Unbound drug concentration is thought to determine the pharmacologic effect of a drug. We therefore recommend that naproxen dosing be reduced by at least half in patients with chronic alcoholic liver disease. In the absence of data to the contrary, this recommendation can be extended to individuals with other forms of hepatic disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blaschke TF (1977) Protein binding and kinetics of drugs in liver disease. Clin Pharmacokinet 2: 32–44
Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level time curve. J Pharmacokinet Biopharm 6: 539–546
Giacomini KM, Giacomini JC, Blaschke TF (1980) Absence of effect of heparin of the binding of prazosin and phenytoin to plasma proteins. Biochem Pharmacol 29: 3337–3343
Held Von H (1980) Serumproteinbindung und Eliminationshalbwertszeiten von Naproxen bei Patienten mit hepatozellularem bzw. obstruktivem Ikterus. Arzneimittelforsch 18: 843–846
Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55: 347–359
Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR (1978) Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 24: 411–419
Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI (1977) Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 296: 1495–1497
Roberts RK, Wilkinson GR, Branch RA, Schenker S (1978) Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 75: 479–485
Rowland M, Benet LZ, Graham G (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1: 123–126
Runkel R, Chaplin M, Boost G, Segre E, Forchielli E (1972) Absorption, distribution, metabolism and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci 61: 703–708
Runkel R, Chaplin MD, Sevelius H, Ortega E, Segre E (1976) Pharmacokinetics of naproxen overdoses. Clin Pharmacol Ther 20: 269–277
Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E (1978) Naproxen-probenecid interactions. Clin Pharmacol Ther 24: 706–713
Shand DG, Kornhauser DM, Wilkinson GR (1975) Effects of route of administration and blood flow in hepatic drug elimination. J Pharmacol Exp Ther 195: 424–432
Shull HG, Wilkinson GR, Johnson R, Schenker S (1976) Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84: 420–425
Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NHG (1983) Volume shifts and protein binding estimates in man-application to prednisolone binding in man. J Pharm Sci 72: 1442–1446
Tozer TN, Oie S (1979) Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68: 1203–1204
Upton RA, Buskin JN, Guentert TW, Williams RL, Riegelman S (1980) Convenient and sensitive high-performance liquid chromatography assay for ketoprofen, naproxen and other allied drugs in plasma or urine. J Chromatogr 190: 119–128
Upton RA, Buskin JN, Williams RL, Holford NHG, Riegelman S (1980) Negligible excretion of unchanged ketoprofen, naproxen and probenecid in urine. J Pharm Sci 69: 1254–1257
Williams RL, Blaschke TF, Meffin PJ, Malmon KL, Rowland M (1977) Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21: 301–309
Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, lagrange and spline approximation. J Pharmacokinet Biopharm 6: 79–98
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williams, R.L., Upton, R.A., Cello, J.P. et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 27, 291–296 (1984). https://doi.org/10.1007/BF00542162
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542162